X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
X4 Pharmaceuticals (XFOR) PT Lowered to $10 at Stifel
March 17, 2022 12:43 PM EDTStifel analyst Stephen Willey lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $10.00 (from $18.00) while maintaining a Buy rating.
... MoreX4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c
March 17, 2022 6:08 AM EDTX4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($1.24), $0.56 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.
... More